Our Pipeline

Our Pipeline

AssetPathwayIndicationPreclinicalIND-EnablingPhase IPhase IIPhase III
BT-11LANCL2Ulcerative Colitis
LANCL2Crohn's Disease
NX-13NLRX1Ulcerative Colitis
NLRX1Crohn's Disease
BT-104LANCL2Lupus
LANCL2Rheumatoid Arthritis
BT-111LANCL2Multiple Sclerosis
LANCL2Type 1 Diabetes

BT-11 has the Potential to Exert Anti-Inflammatory Effects within the Gastrointestinal Track

BT-11 is an orally active compound that binds to and activates the LANCL2 pathway. In preclinical studies, BT-11 has demonstrated potent effects on immune function in models of ulcerative colitis and Crohn’s disease. The compound increases anti-inflammatory cytokines, such as IL-10 and FOXP3 while decreasing pro-inflammatory markers, such as MCP1, TNF-alpha, and IFN-gamma in human immune cells. BT-11 is designed to avoid systemic exposure in the body and has the potential to avoid adverse side effects experienced with current therapies, supporting the potential for a safer treatment.

Landos is currently evaluating BT-11 in a Phase 2 study in ulcerative colitis and is planning to initiate a Phase 2 study in Crohn’s disease in 2020.

BT-11 Diagram

Reprogramming Immune Responses in Autoimmune Diseases

NX-13 may be used in Combination or to Complement Available Therapies

NX-13 is an orally active compound that activates NLRX1, a mitochondria-associated receptor pathway that controls the metabolic process of oxidative phosphorylation. Activation of NLRX1 results in decreased NF-kappa B activity, lower production of inflammatory cytokines and reduced differentiation of effector CD4+ T cells. Relative to other treatment approaches, NX-13 has demonstrated potent effects on disease activity and calprotectin biomarker levels in models of inflammatory bowel disease.

The therapeutic mechanism of NX-13 suggests strong potential in patient populations that experience an inadequate response to available treatments.